Top Banner
22

Niosome

May 26, 2015

Download

Documents

Gaurav Kr

Find more related content at www.PharmInfopedia.com
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Niosome
Page 2: Niosome

INTRODUCTION Niosomes are non-ionic surfactant

vesicles obtained on hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or other lipids.

They are vesicular systems similar to liposomes that can be used as carriers of hydrophilic and lipophilic drugs

It is less toxic and improves the therapeutic index of drug by restricting its action to target cells

Page 3: Niosome

Niosomes are a novel drug delivery system, in which the medication is encapsulated in a vesicle.

The niosomes are very small, and microscopic in size. Their size lies in the nanometric scale.

Niosomes are unilamellar or multilamellar vesicles.The vesicle is composed of a bilayer of non-ionic surface active agents and hence the name niosomes.

A diverse range of materials have been used to form niosomes such as sucrose ester surfactants and polyoxyethylene alkyl ether surfactants, alkyl ester, alkyl amides, fatty acids and amino acid compound.

Page 4: Niosome

Structure of NiosomesNiosomes are microscopic lamellar structures which are formed

on the admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether class and cholesterol with subsequent hydration in aqueous media.

The bilayer in the case of niosomes is made up of non-ionic surface active agents rather than phospholipids as seen in the case of liposomes.

Most surface active agents when immersed in water yield micellar structures, however some surfactants can yield bilayer vesicles which are niosomes.

Niosomes may be unilamellar or multilamellar depending on the method used to prepare them.

Page 5: Niosome

The niosome is made of a surfactant bilayer with its hydrophilic ends exposed on the outside and inside of the vesicle, while the hydrophobic chains face each other within the bilayer.

Hence, the vesicle holds hydrophilic drugs within the space enclosed in the vesicle, while hydrophobic drugs are embedded within the bilayer itself.

Page 6: Niosome

The figure below will give a better idea of what a niosome looks like and where the drug is located within the vesicle ,

Page 7: Niosome

Liposomes Niosomes1) They are expensive. 1) They are not expensive.

2) Ingredients like phospholipids are chemically unstable.

2) Ingredients like Surfactant are chemically stable.

3)It require special storage and handling .

3) Not require special storage and handling.

4) liposomes are made from neutral or charged double chained phospholipids.

4) Niosomes are made of uncharged single-chain surfactant molecules.

5) liposomes increase the bioavailability of the drug and reduce the clearance.

5) Niosomes also increase the bioavailability of the drug and reduce the clearance.

Comparison of Niosomes v/s Liposomes

Niosomes can also be used for targeted drug delivery, similar to liposomes.

Page 8: Niosome

Advantages of NiosomesThe vesicle suspension being water based offers greater patient

compliance over oil based systems Since the structure of the niosome offers place to accommodate

hydrophilic, lipophilic as well as ampiphilic drug moieties, they can be used for a variety of drugs.

The characteristics such as size, lamellarity etc. of the vesicle can be varied depending on the requirement.

The vesicles can act as a depot to release the drug slowly and of controlled release.

Other advantages of niosomes are:They are osmotically active and stable. They increase the stability of the entrapped drug Handling and storage of surfactants do not require any special

conditions Can increase the oral bioavailability of drugs

Page 9: Niosome

o Can enhance the skin penetration of drugso They can be used for oral, parenteral as well topical useo The surfactants are biodegradable, biocompatible, and non-

immunogenic o Improve the therapeutic performance of the drug by protecting it

from the biological environment and restricting effects to target cells, thereby reducing the clearance of the drug.

o The niosomal dispersions in an aqueous phase can be emulsified in a non-aqueous phase to control the release rate of the drug and administer normal vesicles in external non-aqueous phase.

o High patient compliance in comparison with oily dosage forms.o Accommodate drug molecules with a wide range of solubilities.o Characteristics of the vesicle formulation are variable and

controllableo Osmotically active and stable, as well as they increase the stability

of entrapped drug.o Biodegradable, biocompatible and nonimmunogenic.

Page 10: Niosome

Method of PreparationA. Ether injection method• Introduce a solution of surfactant dissolved in

diethyl ether into warm water maintained at 60°C. 

• Surfactant mixture in ether is injected through 14-gauge needle into an aqueous solution of material.

B .  Hand shaking method (Thin film hydration technique)

• Surfactant and cholesterol are dissolved in a volatile organic solvent

• Organic solvent is removed at room temperature using rotary evaporator leaving a thin layer of solid mixture deposited on the wall of the flask

• Dried surfactant film can be rehydrated with aqueous phase at 0-60°C with gentle agitation

Page 11: Niosome

C . Sonication• Aliquot of drug solution in buffer is added to

the surfactant/cholesterol mixture in a 10-ml glass vial

• Mixture is probe sonicated at 60°C for 3 minutes using a sonicator with a titanium probe to yield niosomes.

D. Multiple membrane extrusion method • Mixture of surfactant, cholesterol and dicetyl

phosphate in chloroform is made into thin film by evaporation

• The film is hydrated with aqueous drug solution and the resultant suspension extruded through polycarbonate membranes

Page 12: Niosome

E. Reverse Phase Evaporation Technique• Cholesterol and surfactant (1:1) are dissolved in a

mixture of ether and chloroform.• An aqueous phase containing drug is added to this

and the resulting two phases are sonicated at 4-5°C. 

• organic phase is removed at 40°C under low pressure

• The resulting viscous niosome suspension is diluted with PBS and heated on a water bath at 60°C for 10 min to yield niosomes.

F. Aqueous Dispersion Method• Microdispersion of aqs.media containing solute for

encapsulation• Controlled temp. and agitation provides vesicles

Page 13: Niosome

Table 1: Drugs incorporated into niosomes by various methods

Method of preparation

Drug incorporated

Ether Injection Sodium stibogluconate

Doxorubicin

Hand Shaking Methotrexate Doxorubicin

Sonication 9-desglycinamide 8-arginine Vasopressin Oestradiol

Page 14: Niosome

Separation of Unentrapped Drug1. Dialysis  The aqueous niosomal dispersion is dialyzed in a

dialysis tubing against phosphate buffer or normal saline or glucose solution.

2. Gel Filtration  The unentrapped drug is removed by gel filtration

of niosomal dispersion through a Sephadex-G-50 column and elution with phosphate buffered saline or normal saline.

3. Centrifugation The niosomal suspension is centrifuged and the supernatant is separated. The pellet is washed and then resuspended to obtain a niosomal suspension free from unentrapped drug.

Page 15: Niosome

Characterization of NiosomesA. Entrapment Efficiency• Entrapment efficiency = (Amount

entrapped total amount) x 100

B. Vesicle Morphology• Light Microscopy• Photon Correlation Microscopy• Freeze Fracture Electron Microscopy• Confocal laser scanning Microscopy• SEM • TEM

C. In-vitro release

Page 16: Niosome

Factors affecting vesicles size, entrapment efficiency and release characteristics

DrugAmount and type of surfactantCholesterol content Methods of preparation

Page 17: Niosome

Marketed Products

Lancome has come out with a variety of anti-ageing products which are based on niosome formulations. L’Oreal is also conducting research on anti-ageing cosmetic products.

Page 18: Niosome

Applications1) Targeting of bioactive agentsa) To reticulo-endothelial system b) To organs other than RES2) Neoplasia Doxorubicin Niosomal delivery of

Doxorubicin to mice bearing S-180 tumor increased their life span and decreased the rate of proliferation of sarcoma

3) Leishmaniasis4) Delivery of peptide drugs Oral delivery of 9-desglycinamide, 8-arginine

vasopressin entrapped in niosomes increase stability of peptide significantly.

Page 19: Niosome

5) Immunological application of niosomes enhance the antibody production in response

to bovine serum albumin6) Niosomes as carriers for Hemoglobin7) Transdermal delivery of drugs by

niosomes e.g. erythromycin

Page 20: Niosome

ConclusionThe concept of incorporating the drug into

niosomes for a better targeting of the drug at appropriate tissue destination .

They presents a structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes

Niosomes are thoughts to be better candidates drug delivery as compared to liposomes due to various factors like cost, stability etc. Various type of drug deliveries can be possible using niosomes like targeting, ophthalmic, topical, parentral, etc. 

Page 21: Niosome

REFERENCESVyas S.P. , Khar R.K. ,Targeted & Controlled

Drug Delivery, Novel Carrier Systems, CBS Publication ,2002 ,Page No.249-279

Malhotra M. and Jain N.K. Niosomes as Drug Carriers. Indian Drugs 1994, Page No: 81-86.

Chandraprakash K.S., Udupa N., Umadevi P. and Pillai G.K. Pharmacokinetic evaluation of surfactant vesicles containing methotrexate in tumor bearing mice. Int. J. Pharma. 1990; R1-R3: 61.

www.pharmainfo.net www.sciencedirect.com

Page 22: Niosome